Form 4: Corcept Therapeutics Executive Exercises Options and Sells Shares

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, exercised stock options and sold shares on October 1, 2024, according to a Form 4 filing with the SEC.

Summary

• Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, filed a Form 4 with the SEC.
• On September 27, 2024, Robb acquired 415 shares of common stock indirectly through a custodial account for a child.
• On October 1, 2024, Robb exercised options to acquire 11,000 shares at a price of $3.29 per share.
• Also on October 1, 2024, Robb sold 11,000 shares at a price of $46.28 per share.
• Following these transactions, Robb directly owns 22,772 shares and indirectly owns 9,665 shares through a custodial account.
• Robb also owns 14,037 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares for personal financial management.

Stakeholder Impact

• The sale of shares by a high-ranking officer could be perceived negatively by some investors, although it is a common practice.
• The transactions have a minimal impact on the company's operations or financial position.

Key Dates